drugset / Trial / NCT07656909

Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP

NCT07656909

Phase 2/3 Recruiting 76 enrolled Yi Ji
RandomizedParallel-groupSingle-blindTreatment

Summary

This randomized clinical trial evaluates if low-dose sirolimus (target trough 4-8 ng/mL) combined with prednisolone is noninferior in efficacy but superior in safety compared to standard high-dose sirolimus (target trough 10-15 ng/mL) combined with prednisolone in pediatric patients with kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon (KHE with KMP), with participants randomized 1:1 to receive the assigned regimen, undergo routine blood and imaging monitoring, and be evaluated for clinical response and adverse events.

Timeline

Start
2026-06-16
Primary completion
2027-12-31
Completion
2028-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule Oral